Although cognitive-behavioral therapy (CBT) has shown efficacy in reducing symptoms and rates of mood relapse in adolescents at high risk for severe mood disorders (SMD; i.e., bipolar I/II disorder and recurrent or unremitting major depression), a significant limitation to the CBT's efficacy is the low rate of participant adherence to the prescribed between-session homework tasks. Mobile health applications have the potential to improve adherence to and acceptance of treatment through embedded treatment content, skill-practice, thought and symptom monitoring, all of which are facilitated by reward contingencies and notifications. This study examines whether a mobile application-enhanced CBT can improve participant adherence and treatment acceptance for adolescents at high risk for SMD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
91
Group-based transdiagnostic cognitive-behavioral treatment
UCLA Semel Institute
Los Angeles, California, United States
Treatment Skill Practice
Sum of all treatment skill practices completed through the course of the treatment (based on adolescent report).
Time frame: 9-week treatment period
Psychosocial Treatment Compliance Scale
Clinician-rated of participant overall treatment compliance. Scores range from 17-85 (17 5-point Likert scale items) with higher scores indicating greater treatment compliance.
Time frame: 9-week treatment
Mobile Application Use
Frequency of mobile application (app) usage within the condition that received the mobile application, ranging from 0 to unlimited maximum with higher scores indicating more app usage.
Time frame: 9-week treatment period
Mobile Application Usability Scale
Mobile application (app) acceptability as rated on a 5-point scale (i.e., minimum = 1, maximum = 5) with higher values indicating greater acceptability
Time frame: Measured at the end of the 9-week treatment period
Children's Depression Rating Scale, Revised
Measures depressive symptom severity. Scores range from 17-113 (14 7-point items and 3 5-point items) with higher scores indicating greater depressive severity.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Young Mania Rating Scale
Measure manic symptom severity. Scores range from 0-60 (7 5-point items and 4 9-point items) with higher scores indicating greater manic severity.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Clinical Global Assessment Scale
Measures overall functioning on a 1-100 scale, with higher scores indicating better functioning.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Clinical Global Impression
Measures overall clinical functioning from 1-7, with higher scores indicating greater psychiatric severity.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Symptom Checklist 90
Participant-reported psychiatry symptoms. Scores range from 0 - 360 (90 5-point Likert items) with higher scores indicating greater symptom severity.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Difficulties With Emotion Regulation
Participant reported their difficulties with emotion regulation. Scores range from 36 - 180 (36 5-point items) with higher scores indicating greater distress.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
KINDL
Quality of life measure. Scores range from 0 - 120 (30 5-point items) with higher scores indicating better quality of life.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
Depression Anxiety & Stress Scale
Parent reported mood, anxiety and stress. Scores range from 0 - 63 (21 4-point items) with higher scores indicating greater distress.
Time frame: Measured prior to treatment (0 months), at the end of the 9-week treatment, and the end of the 21-week study period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.